RxDoctor Payments Data

Anitha Nallari, MD

Hematology & Oncology · Columbus, OHNPI 1881649879

Payments from drug & device makers

$1,254in general payments, 2019–2025

Across 53 payments — averaging $23.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$258
  • AstraZeneca$197
  • Novartis$174
  • Eli Lilly$94
  • Takeda Pharmaceuticals U.S.A., Inc.$75
  • Eisai Inc.$56
  • plus $399 from 16 others

What the payments were for

  • Food & beverage$83366%
  • Education$42134%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,254 in reported general payments places this provider in the 30th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$91,315
Medicare patients
299
Services billed
802

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide32$528,246
QinlockRipretinib11$445,753
JakafiRuxolitinib Phosphate24$420,383
BosulifBosutinib18$335,464
PomalystPomalidomide12$274,231
VerzenioAbemaciclib13$204,743
Lenalidomide23$187,170
Abiraterone Acetate30$95,102
VenclextaVenetoclax11$79,387
EliquisApixaban19$10,539
Ondansetron Hcl34$2,327
Exemestane14$1,765
Anastrozole117$1,574
Letrozole91$1,118
Dexamethasone75$819

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$47$528,24632 claims
PfizerBosulif, Eliquis$49$346,00337 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$16$274,23112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →